(ELAN) Elanco Animal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28414H1032

Parasiticides, Vaccines, Therapeutics, Antibiotics, Feed Additives

Stock: Pharmaceuticals
Age 7.3y

MCap 12,188m
Avg Vol 4.56M (106M USD)

Beta 1.300
Volatility 42.05%

EPS (Earnings per Share)

EPS CAGR: -54.69%
EPS Trend: -41.1%

Last SUE: -3.00
Qual. Beats: 0

Revenue

Rev. CAGR: 0.57%
Rev. Trend: 8.2%

Last SUE: 2.58
Qual. Beats: 3

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	42.1%
Value at Risk 5%th	56.7%
Relative Tail Risk	-18.05%

Reward TTM
Sharpe Ratio	1.59
Alpha	84.77
CAGR/Max DD	0.41

Character TTM
Hurst Exponent	0.455
Beta	1.300
Beta Downside	1.244

Drawdowns 3y
Max DD	56.10%
Mean DD	20.65%
Median DD	21.31%

Description: ELAN Elanco Animal Health January 06, 2026

Elanco Animal Health (NYSE: ELAN) develops, manufactures and markets a broad portfolio of animal-health products for pets and livestock, ranging from parasiticides (Seresto, Credelio) and vaccines to therapeutics such as Galliprant for canine osteoarthritis. Its farm-animal line includes medicated feed additives, injectable antibiotics (Baytril), and disease-prevention vaccines for cattle, swine and poultry (e.g., Rumensin, Maxiban).

Key financial metrics from the most recent FY2023 filing show total revenue of approximately $3.6 billion, with pet-care sales contributing roughly 45 % and livestock products the remainder; adjusted EBITDA margin hovered around 12 %, reflecting ongoing cost-discipline but also pressure from higher raw-material costs. The pet-care segment is benefitting from a secular 5-6 % CAGR in U.S. pet spending, while the livestock side faces tighter regulatory scrutiny on antibiotic use, a factor that could reshape product mix in the next 12-24 months.

Assuming the company can sustain its pipeline of next-generation parasiticides and expand its Galliprant indication set, the upside potential is tied to two drivers: (1) continued growth in the premium-pet market, which historically outperforms broader consumer cycles, and (2) the global demand for sustainable livestock production, which may increase adoption of feed-additive solutions despite regulatory headwinds. A downside risk is a possible slowdown in veterinary clinic visits if economic conditions tighten, which would directly depress prescription-drug volumes.

For a deeper dive into ELAN’s valuation sensitivities and comparable peer analysis, you might find the data tools on ValueRay useful.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (36.0m TTM) > 0 and > 6% of Revenue (6% = 275.5m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -0.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 44.39% (prev 45.91%; Δ -1.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 629.0m > Net Income 36.0m (YES >=105%, WARN >=100%)

Net Debt (3.52b) to EBITDA (891.0m) ratio: 3.95 <= 3.0 (WARN <= 3.5)

Current Ratio 2.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (496.8m) change vs 12m ago -0.18% (target <= -2.0% for YES)

Gross Margin 46.37% (prev 42.68%; Δ 3.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 34.22% (prev 33.53%; Δ 0.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.93 (EBITDA TTM 891.0m / Interest Expense TTM 237.0m) >= 6 (WARN >= 3)

Altman Z'' 0.31

(A) 0.15 = (Total Current Assets 3.49b - Total Current Liabilities 1.46b) / Total Assets 13.55b

(B) -0.14 = Retained Earnings (Balance) -1.91b / Total Assets 13.55b

(D) -0.31 = Book Value of Equity -2.10b / Total Liabilities 6.80b

Total Rating: 0.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 41.50

1. Piotroski 3.50pt

2. FCF Yield 2.30%

3. FCF Margin 7.88%

4. Debt/Equity 0.60

5. Debt/Ebitda 3.95

6. ROIC - WACC (= -6.85)%

7. RoE 0.55%

8. Rev. Trend 8.22%

9. EPS Trend -41.14%

What is the price of ELAN shares?

As of January 20, 2026, the stock is trading at USD 24.53 with a total of 6,590,900 shares traded.
Over the past week, the price has changed by +2.76%, over one month by +10.00%, over three months by +12.94% and over the past year by +103.74%.

Is ELAN a buy, sell or hold?

Elanco Animal Health has received a consensus analysts rating of 3.87. Therefore, it is recommended to buy ELAN.

Strong Buy: 6
Buy: 1
Hold: 8
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ELAN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	25	1.9%
Analysts Target Price	25	1.9%
ValueRay Target Price	26.3	7.3%

ELAN Fundamental Data Overview January 19, 2026

P/E Trailing = 350.4286
P/E Forward = 23.3645
P/S = 2.6548
P/B = 1.8059
P/EG = 4.2476
Revenue TTM = 4.59b USD
EBIT TTM = 221.0m USD
EBITDA TTM = 891.0m USD
Long Term Debt = 3.96b USD (from longTermDebt, last quarter)
Short Term Debt = 62.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.52b USD (from netDebt column, last quarter)
Enterprise Value = 15.71b USD (12.19b + Debt 4.02b - CCE 505.0m)
Interest Coverage Ratio = 0.93 (Ebit TTM 221.0m / Interest Expense TTM 237.0m)
EV/FCF = 43.39x (Enterprise Value 15.71b / FCF TTM 362.0m)
FCF Yield = 2.30% (FCF TTM 362.0m / Enterprise Value 15.71b)
FCF Margin = 7.88% (FCF TTM 362.0m / Revenue TTM 4.59b)
Net Margin = 0.78% (Net Income TTM 36.0m / Revenue TTM 4.59b)
Gross Margin = 46.37% ((Revenue TTM 4.59b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 53.39% (prev 46.49%)
Tobins Q-Ratio = 1.16 (Enterprise Value 15.71b / Total Assets 13.55b)
Interest Expense / Debt = 1.29% (Interest Expense 52.0m / Debt 4.02b)
Taxrate = 30.74% (150.0m / 488.0m)
NOPAT = 153.1m (EBIT 221.0m * (1 - 30.74%))
Current Ratio = 2.40 (Total Current Assets 3.49b / Total Current Liabilities 1.46b)
Debt / Equity = 0.60 (Debt 4.02b / totalStockholderEquity, last quarter 6.75b)
Debt / EBITDA = 3.95 (Net Debt 3.52b / EBITDA 891.0m)
Debt / FCF = 9.72 (Net Debt 3.52b / FCF TTM 362.0m)
Total Stockholder Equity = 6.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.27% (Net Income 36.0m / Total Assets 13.55b)
RoE = 0.55% (Net Income TTM 36.0m / Total Stockholder Equity 6.49b)
RoCE = 2.11% (EBIT 221.0m / Capital Employed (Equity 6.49b + L.T.Debt 3.96b))
RoIC = 1.43% (NOPAT 153.1m / Invested Capital 10.73b)
WACC = 8.27% (E(12.19b)/V(16.21b) * Re(10.71%) + D(4.02b)/V(16.21b) * Rd(1.29%) * (1-Tc(0.31)))
Discount Rate = 10.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.41%
[DCF Debug] Terminal Value 73.85% ; FCFF base≈369.2m ; Y1≈305.0m ; Y5≈220.3m
Fair Price DCF = 0.64 (EV 3.84b - Net Debt 3.52b = Equity 320.1m / Shares 496.9m; r=8.27% [WACC]; 5y FCF grow -20.95% → 2.90% )
EPS Correlation: -41.14 | EPS CAGR: -54.69% | SUE: -3.00 | # QB: 0
Revenue Correlation: 8.22 | Revenue CAGR: 0.57% | SUE: 2.58 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.35 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=10
EPS next Year (2026-12-31): EPS=1.04 | Chg30d=-0.001 | Revisions Net=+3 | Growth EPS=+10.1% | Growth Revenue=+5.6%

Additional Sources for ELAN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle